VEEV Stock Risk & Deep Value Analysis

Veeva Systems Inc

DVR Score

5.9

out of 10

Proceed with Caution

What You Need to Know About VEEV Stock

We analyzed Veeva Systems Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran VEEV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Apr 13, 2026•Run Fresh Analysis →

VEEV Risk Analysis & Red Flags

What Could Go Wrong

Veeva's primary risk lies in a deceleration of its core subscription revenue growth as the market matures or if key competitors make significant inroads. Given its premium valuation (even with the recent dip), any sustained drop in growth rates below expectations could lead to significant de-rating by the market, impacting investor confidence and share price.

Risk Matrix

Overall

Moderate

Financial

Low

Market

Medium

Competitive

Medium

Execution

Low

Regulatory

Low

Red Flags

⚠
Recent Citigroup downgrade to Neutral (April 10, 2026) suggests some analyst caution on valuation.
⚠
Stock hit a 52-week low on April 8, 2026, indicating negative short-term market sentiment despite strong fundamentals.

Upcoming Risk Events

📅
Q1 FY2027 earnings miss or weaker-than-expected FY2027 guidance
📅
Increased competitive pressure or pricing wars in core segments

When to Reconsider

🚪
Exit if subscription services revenue growth consistently falls below 10% YoY.
🚪
Sell if non-GAAP operating margin shows sustained decline over multiple quarters.

Unlock VEEV Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Veeva Systems is a high-quality, market-leading SaaS provider uniquely positioned within the growing and complex life sciences sector. Its deep competitive moats, high recurring revenue, and consistent execution make it a strong long-term compounder. The recent valuation reset provides a more attractive entry point, allowing investors to capitalize on its continued expansion within a substantial total addressable market and its ability to capture a larger share of the biopharma cloud market.

Is VEEV Stock Undervalued?

Veeva Systems remains a top-tier software provider for the life sciences industry, boasting strong competitive moats and a high recurring revenue model. The recent Q4 FY2026 earnings beat, robust FY2027 guidance, and significant share buyback program underscore its exceptional execution and improving profitability. The company's valuation has become more attractive following a recent price drop to a 52-week low ($151.43, down from $~173.2), reducing its market cap to $24.73B from $28.42B just 8 days ago. This lower base, combined with forward P/E and PEG ratios now below industry averages, slightly improves the long-term risk/reward for a 10x growth scenario, making it marginally less improbable. However, achieving such exponential growth from its current large-cap valuation remains highly ambitious, preventing a significantly higher score despite its fundamental strengths. The recent Citigroup downgrade and stock hitting a 52-week low indicate cautious near-term market sentiment, but the underlying business health is strong.

Unlock the full AI analysis for VEEV

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

VEEV Price Targets & Strategy

12-Month Target

$210.00

Bull Case

$260.00

Bear Case

$130.00

Valuation Basis

24.6x forward P/E multiple applied to projected FY2027 Non-GAAP EPS of $8.52 (based on Q1 FY27 consensus).

Entry Strategy

Dollar-cost average between $145-$155 (near 52-week low and recent support zone around $151.43).

Exit Strategy

Take partial profit at $210 (12M target), consider full exit if fundamental growth decelerates below 10% YoY, or if operating margins consistently decline. Stop loss at $130 (break of 52-week low by significant margin).

Portfolio Allocation

5% for moderate risk tolerance.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is VEEV Financially Healthy?

Valuation

P/E Ratio

27.21

Forward P/E

24.18

EV/EBITDA

20.37

PEG Ratio

1.42

Price/Book

8.92

Price/Sales

7.65

Profitability

Gross Margin

75.53%

Operating Margin

28.68%

Net Margin

28.44%

Return on Equity

13.41%

Revenue Growth

16.34%

EPS

$5.45

Balance Sheet

Current Ratio

4.89

Quick Ratio

4.81

Cash & Equivalents

$1.04B

Cash Flow

Operating Cash Flow

$801.00M

Free Cash Flow

$712.00M

EBITDA

$580.00M

Other

Beta (Volatility)

1.02

Does VEEV Have a Competitive Moat?

Moat Rating

🏰 Wide

Moat Trend

Stable/Expanding

Moat Sources

3 Identified

Switching CostsIntangible Assets/IPNetwork Effects

Veeva's moat is highly durable due to the specialized, mission-critical nature of its software within the heavily regulated life sciences industry. The cost and disruption associated with switching vendors are immense, and its deep industry-specific functionalities are difficult to replicate, ensuring long-term customer stickiness.

Moat Erosion Risks

•Emergence of a truly disruptive AI-driven platform that significantly simplifies or automates core life sciences processes without requiring Veeva's established infrastructure.
•Major changes in global pharmaceutical regulations that could diminish the value or necessity of Veeva's current compliance and workflow solutions.

VEEV Competitive Moat Analysis

VEEV Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (Mixed sentiment due to recent price drop and analyst downgrade, despite strong underlying business performance).

Institutional Sentiment

Neutral (High institutional ownership at ~88.2%, but recent downgrades from Citigroup and price target cuts from Truist suggest some cautiousness among analysts).

Insider Activity (Form 4)

Board authorized $2.0 billion share buyback in January 2026, with $180 million already deployed. No specific Form 4 filings for insider buys/sells detailed in last 90 days from provided research.

Options Flow

Normal options activity (No specific unusual options activity reported in the given research).

Earnings Intelligence

Next Earnings

2026-06-03

Surprise Probability

Medium-High (Historical tendency for beats, but Q1 FY27 consensus implies a slight deceleration in YoY growth compared to Q4 FY26).

Historical Earnings Pattern

Veeva typically sees positive stock price reactions on earnings beats, especially when accompanied by strong guidance. However, recent market sensitivity suggests investors are closely scrutinizing growth deceleration, potentially leading to sell-offs on perceived weaknesses even with beats.

Key Metrics to Watch

Subscription services revenue growthVault CRM customer adoption rates and pipeline updatesNon-GAAP operating margin trendUpdated FY2027 guidance

Competitive Position

Top Competitor

No specific best-in-class competitor identified from research, given Veeva's specialized niche, but indirect competition exists from large enterprise software vendors and smaller specialized point solutions.

Market Share Trend

Gaining (Serves 15 of top 20 biopharma, with Vault CRM expanding to 140 customers live and 10 of top 20 committed).

Valuation vs Peers

Trading at a slightly below-industry-average forward P/E (17.82-19.91 vs. 18.98 industry avg) and below-industry-average PEG ratio (0.75-1.15 vs. 1.13 industry avg), suggesting a reasonable valuation relative to its quality and growth profile.

Competitive Advantages

•Deep industry-specific domain expertise and regulatory compliance focus
•High switching costs due to embedded nature of software in critical workflows
•Integrated cloud platform (Veeva Vault) offering comprehensive solutions

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive VEEV Stock Higher?

Near-Term (0-6 months)

•Q1 FY2027 Earnings on 2026-06-03
•Continued expansion of Vault CRM customer base (e.g., securing additional top 20 biopharma clients)

Medium-Term (6-18 months)

•Strategic partnerships to expand market reach or integrate new technologies
•Successful adoption of new R&D cloud solutions in emerging life sciences segments

Long-Term (18+ months)

•Further digitalization and cloud transformation across the entire life sciences value chain
•Expansion into adjacent highly regulated industries beyond life sciences

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for VEEV?

✓
Acceleration in subscription revenue growth and billings trend
✓
Consistent expansion of non-GAAP operating margins and free cash flow generation

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How Veeva Systems Inc Makes Money

Veeva Systems provides specialized cloud-based software solutions to the global life sciences industry, including pharmaceutical, biotechnology, and medical device companies. Its software helps these companies manage a wide array of mission-critical functions, from drug discovery and clinical trials (R&D Cloud) to commercial operations, sales, and marketing (Commercial Cloud). Veeva primarily generates revenue through recurring subscription fees for access to its highly integrated and industry-specific software applications, which become deeply embedded in customer workflows and are supported by professional services.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Veeva Systems Inc (VEEV)?

As of April 13, 2026, Veeva Systems Inc has a DVR Score of 5.9 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Veeva Systems Inc?

Veeva Systems Inc's market capitalization is approximately $24.7B..

What is the risk level for VEEV stock?

Our analysis rates Veeva Systems Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of VEEV?

Veeva Systems Inc currently has a price-to-earnings (P/E) ratio of 27.2. This is in line with broader market averages.

Is Veeva Systems Inc's revenue growing?

Veeva Systems Inc has reported revenue growth of 16.3%. The company is showing strong top-line momentum.

Is VEEV stock profitable?

Veeva Systems Inc has a profit margin of 28.4%. This indicates strong profitability.

How often is the VEEV DVR analysis updated?

Our AI-powered analysis of Veeva Systems Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 13, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VEEV (Veeva Systems Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.